Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.
Oragenics Inc. (NYSE American: OGEN), a biotechnology firm specializing in intranasal pharmaceuticals for neurological disorders, has announced a significant financial move to bolster its research and development activities. The company has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, with each unit priced at $25.00. This strategic offering could generate gross proceeds of up to $20 million, earmarked for advancing the ONP-2 concussion trials, supporting ongoing R&D initiatives, repaying a $3 million bridge note, and addressing general corporate needs.
The Warrants included in the offering grant the holder the right to purchase an additional Preferred share at the same $25.00 price, with the Preferred shares being convertible into common stock at $2.50 per share. Dawson James Securities, Inc. serves as the sole placement agent for this transaction, which is anticipated to close on or around July 2, 2025. This financial infusion is pivotal for Oragenics as it seeks to make strides in its mission to develop innovative treatments for neurological disorders and infectious diseases through its proprietary nasal delivery technologies.
For further details on this offering, interested parties can view the full press release here. Oragenics' commitment to addressing unmet medical needs in neurology and infectious diseases underscores the importance of this funding round, which promises to accelerate the development of its promising drug candidates.